hodgkin lymphoma (hl) accounts for about 10% of all childhood cancers. five-year survival rates with modern therapies are now approaching >90-95% as a consequence of its significant sensitivity to both chemotherapy and radiation. the current challenge is to determine how much therapy is needed to improve survival and how to adapt treatment to the patient to prevent these long term toxicities. t...

results one-, three-, five-, and ten-year graft survival was 93.8%, 86.8%, 76.6%, and 37.4%, respectively. the results of the joint model showed that risk indicators, such as serum creatinine level (p < 0.0001, hr = 1.82), patient’s age (p = 0.006, hr = 1.03), and anti-thymocytes globulin (p = 0.019, hr = 2.57) had a significant relationship to graft survival. conclusions in general, our study ...

conclusions by controlling the modifiable risk factors and modality of treatment in our study, physicians can reach more effective treatment. results at the end of the study, long-term graft failure was seen in 27 (10.2%) cases. one-year and 2-year graft survival after diagnosis of cancer were 93.6% and 91.7%, respectively. the univariate analysis showed that the incidence of chronic graft loss...

The development of vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors for the treatment of renal cancer is a real success story. Moving from toxic and minimally efficacious interleukin (IL)-2 and interferon to six US Food and Drug Administration (FDA)-approved agents has significantly benefited our patients, and has led to a dramatic...